Fig. 1From: Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I studyBest percentage change from baseline in target lesion size in individual patients. The patient with CR had only 1 target lesion: a lymph node that shrunk to < 10 mm. BORR = best overall response rate; CR = complete response; PR = partial response; PD = progressive disease; SD = stable diseaseBack to article page